Bioanalytical System Lowered to Sell at TheStreet (BASI)
Bioanalytical System (NASDAQ:BASI) was downgraded by research analysts at TheStreet from a “hold” rating to a “sell” rating in a report released on Friday, AR Network reports.
The analysts wrote, “Bioanalytical Systems (BASI) has been downgraded by TheStreet Ratings from hold to sell. The company’s weaknesses can be seen in multiple areas, such as its unimpressive growth in net income and generally high debt management risk.”
Bioanalytical System (NASDAQ:BASI) traded down 0.69% on Friday, hitting $2.751. The stock had a trading volume of 1,682 shares. Bioanalytical System has a 52 week low of $1.25 and a 52 week high of $3.80. The stock’s 50-day moving average is $3.05 and its 200-day moving average is $2.05. The company’s market cap is $21.7 million.
Bioanalytical System (NASDAQ:BASI) last announced its earnings results on Thursday, February 13th. The company reported $0.04 earnings per share (EPS) for the quarter. The company had revenue of $6.22 million for the quarter, compared to the consensus estimate of $5.80 million.
Bioanalytical Systems, Inc and its subsidiaries are engaged in research services and other services related to pharmaceutical development.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.